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Background: Progress towards HIV, hepatitis B virus 
(HBV) and hepatitis C virus (HCV) elimination requires 
local prevalence estimates and linkage to care (LTC) of 
undiagnosed or disengaged cases. Aim: We aimed to 
estimate seroprevalence, factors associated with posi-
tive blood-borne virus (BBV) serology and numbers 
needed to screen (NNS) to detect a new BBV diagnosis 
and achieve full LTC from emergency department (ED) 
BBV testing. Methods: During a 9-month programme 
in an ED in east London, England, testing was offered 
to adult attendees having a full blood count (FBC). We 
estimated factors associated with positive BBV serol-
ogy using logistic regression and NNS as the inverse 
of seroprevalence. Estimates were weighted to the 
age, sex and ethnicity of the FBC population. Results: 
Of 6,211 FBC patients tested, 217 (3.5%) were positive 
for at least one BBV. Weighted BBV seroprevalence 
was 4.2% (95% confidence interval (CI): 3.6–4.9). 
Adjusted odds ratios (aOR) of positive BBV serology 
were elevated among patients that were: male (aOR: 
2.7; 95% CI: 1.9–3.9), 40–59 years old (aOR: 1.9; 95% 
CI: 1.4–2.7), of Black British/Black other ethnicity 
(aOR: 1.8; 95% CI: 1.2–2.8) or had no fixed address 
(aOR: 2.9; 95% CI: 1.5–5.5). NNS to detect a new BBV 
diagnosis was 154 (95% CI: 103–233) and 135 (95% 
CI: 93–200) to achieve LTC. Conclusions: The low NNS 
suggests routine BBV screening in EDs may be worth-
while. Those considering similar programmes should 
use our findings to inform their assessments of antici-
pated public health benefits.
Introduction
Global strategies to eliminate the blood-borne viruses 
(BBV) hepatitis B virus (HBV), hepatitis C virus (HCV) 
and HIV as a public health threat by 2030 [1,2] require 
estimates of local prevalence in population subgroups 
[3], detection of undiagnosed infection, better linkage 
to care (LTC) and treatment of infected individuals [4-7]. 
In the United Kingdom (UK), the BBV burden occurs dis-
proportionately in London, a demographically diverse 
city that is home to a third of all people diagnosed 
with HCV in England [8] and 40% of those living with 
HIV in the UK [9]. The city also has a rate of positive 
hepatitis B (HBV) tests (1.1%) from antenatal screen-
ing that is more than double the English average [10]. 
London-wide modelled prevalence estimates for peo-
ple 15–59 years old exist for HCV (1.2%; 95% credible 
interval (CrI): 0.9–1.8) [11] and diagnosed HIV (0.57%; 
95% confidence interval (CI): 0.56–0.58) [12], but are 
not yet available for HBV. Rates of infection vary con-
siderably according to demographic and lifestyle risk 
factors [4,8,10,13,14] and 11% of HIV, 40% of HCV and 
an unknown number of HBV infections in London [8,9] 
are thought to be undiagnosed.
Current UK guidelines recommend routine screening for 
HIV in a range of medical settings, including hospital 
emergency departments (EDs) in areas of high preva-
lence (> 0.2%) [15,16]. Similar recommendations for HBV 
and HCV do not exist, with testing usually occurring in 
specialist addiction units, prisons and sexual health 
centres. Short-duration screening campaigns in urban 
EDs in the UK have detected high BBV seroprevalence 
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of between 1.2–2.6% for HCV [17,18], 0.7% for HBV [17] 
and 0.2–0.8% for HIV [17,19]. ED testing has shown to 
be acceptable to staff and patients [19] and does not 
adversely affect length of stay when offered to patients 
having routine blood tests [20]. Testing for BBVs in EDs 
is recommended in the United States (US) as part of 
birth-cohort HCV testing [21,22] and universal screen-
ing programmes have been carried out in Europe [23-
25], but until now no prospective combined BBV testing 
programmes of a duration longer than 1 week have 
been reported in the UK.
As an extension of a previous week-long campaign 
named Going Viral [17], we carried out a 9-month pro-
spective BBV testing programme with LTC in the ED 
of an east London hospital to assess the feasibility 
of routinely providing ED-based opt-out testing. The 
programme had complementary clinical and epidemi-
ological components, the former being the focus of a 
separate paper [26]. Here we describe the epidemio-
logical component, which had the following objectives: 
(i) to identify factors associated with the uptake of BBV 
testing and positive BBV serology, (ii) to estimate BBV 
seroprevalence and numbers needed to screen (NNS) 
to detect a new diagnosis and fully link a case to care 
and (iii) to describe the diagnostic status of BBV cases 
and the LTC outcomes achieved in the first 6 months 
after the end of testing.
Methods
Programme overview
Between 20 November 2015 and 7 August 2016, BBV 
opt-out testing was offered to adult ED attendees who 
had the capacity to consent verbally and had a full 
blood count (FBC) as part of routine care. An addi-
tional blood sample was taken and tested for HIV anti-
gen/antibody, HBV surface antigen (HBsAg) and HCV 
antibody (HCV-Ab), with reactive HCV samples subse-
quently tested for HCV RNA. The specific laboratory 
methods used have been described previously [26]. 
LTC started as soon as the first cases were identified 
and continued after the programme as part of normal 
clinical follow-up.
Case definitions
Infection-specific cases
HIV, HBV and HCV-RNA cases were defined as an ED 
attendee who had a FBC with a reactive result for HIV 
antigen/antibody, HBsAg or HCV RNA, respectively. An 
inclusion criterion of having been tested for at least 
two BBVs reflected the programme’s intention of test-
ing patients for multiple infections, while accepting 
that patients could choose to opt out of specific tests.
BBV case
A BBV case was defined as an ED attendee who had a 
FBC and was tested for at least two BBVs, with a reac-
tive result for HIV antigen/antibody and/or HBsAg and/
or HCV RNA.
Diagnostic status of cases
All cases were assigned to one of five categories of 
diagnostic status based on information they provided 
when they were contacted by phone to notify them of 
their positive result, or from searches of hospital labo-
ratory records (Table 1). While diagnostic status was 
obtained for all patients positive for HCV-Ab [26], it is 
only presented for HCV-RNA cases.
Cases requiring linkage to care
Cases requiring linkage to care (RLTC) were defined as 
living BBV cases whose diagnostic status was classi-
fied as new diagnosis, known-disengaged, known-
unknown or uncontactable. Known-engaged BBV cases 
did not require LTC, but were included in seropreva-
lence estimates.
Linkage to care outcomes
The clinical team’s records of attempts to contact 
cases and the number of clinics/inpatient consulta-
tions attended by those RLTC were used to assign three 
sequential LTC outcomes: notified (informed of posi-
tive test result), partially linked to care (notified and 
attended one clinic or inpatient consultation) and fully 
linked to care (notified and attended either two clinics 
or one inpatient consultation and one clinic).
Table 1
Categories of diagnostic status of blood-borne virus cases, hospital emergency department testing programme, London, 
United Kingdom, 2015–2016
Category Information obtained from the patient or through hospital laboratory records
Known-engaged Patient had been previously diagnosed or had a previous positive test result on hospital laboratory records and was enrolled in healthcare to treat or manage the disease
Uncontactable Patient could not be contacted to be notified of their diagnosis and had no previous test result on hospital records so diagnostic status remained unknown
New diagnosis Patient informed us that their diagnosis was not previously known to them
Known-disengaged Patient had been previously diagnosed or had a previous positive test result on hospital laboratory records, but was lost to follow-up from healthcare to treat or manage the disease
Known-unknown Patient had a previous positive result in hospital records, but could not be contacted to determine whether they were engaged in healthcare
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Data collection and management
Datasets of ED attendees, FBC patients and BBV tests 
were extracted from the hospital IT system and medical 
staff recorded the follow-up of cases RLTC. Data were 
imported into Stata 14.1 (Stata Corp, College Station, 
Texas, US) for manipulation and analysis. We grouped 
variables related to patient demographics—sex, age, 
ethnicity and whether or not they had a fixed address 
(‘no fixed address’ being a proxy for homelessness)—
into clinically and epidemiologically relevant catego-
ries and also created variables relating to ED arrival 
and waiting times, categorised as day/night, weekday/
weekend and quartiles of time from arrival to assess-
ment. We excluded duplicate records, patients <  18 
years old, those missing a hospital number (a unique 
identifier to link a patient between datasets) or those 
in the BBV tests dataset that did not have a corre-
sponding entry in the FBC or ED datasets. For patients 
with multiple tests or visits to the ED, we retained the 
most complete test record, i.e. the one that showed a 
change in infection status or the earliest record.
Statistical analysis
Factors associated with uptake of BBV testing
We described the distribution of patients attending the 
ED, having a FBC and being tested for at least two BBVs 
across patient demographic and ED process variables. 
To estimate factors associated with uptake of BBV 
testing we identified variables associated with test-
ing among all patients having a FBC using chi-squared 
tests. Sex, age, time of arrival in the ED and if they 
had no fixed address were subsequently included as 
independent variables in a logistic regression model, 
with BBV testing as the dependent variable to obtain 
adjusted odds ratios (aOR) for the association between 
each variable and BBV testing. We excluded patients 
whose records were missing their sex or waiting time, 
Figure 
Flow of patients through the testing and linkage to care pathway, hospital emergency department testing programme, 
London, United Kingdom, 2015–2016
ED attendees
65,136 
FBC patients
24,981  (38%)
Tested for at least 2 BBVs
6,211 (25%)
BBV casesa
217 (3.5%)
HIV cases
71 (1.2%)
HBV cases
54 (0.9%)
HCV-RNA cases
100 (1.6%)
HCV-Ab positive
147 (2.4%)
Diagnostic
status 
Uncontactable
New diagnosis
Known-engaged
Known-disengaged
Known-unknown
20 (9%)
31 (14%)
129 (59% of all cases)
32 (15%)
5 (2%)
1 (1%)
10 (14%)
55 (77% of all cases)
5 (7%)
0 (0%)
9 (17%)
8 (15%)
26 (48% of all cases)
10 (19%)
1 (2%)
10 (10%)
13 (13%)
54 (54% of all cases)
19 (19%)
4 (4%)
Linkage 
to care 
outcomec
Requiring linkage 
to care (RLTC)b
Notified
Partially linked to care
Fully linked to care
Unlinked
86 cases
(40% of all cases)
58 (67% of RLTC)
47 (55%)
35 (41%)
27 (31%)
16 cases
(23% of all cases)
12 (75% of RLTC)
12 (75%)
11 (69%)
4 (25%)
27 cases
(50% of all cases)
17 (63% of RLTC)
13 (48%)
11 (41%)
10 (37%)
44 cases 
(44% of all cases)
29 (66% of RLTC)
22 (50%)
13 (30%)
14 (34%)
BBV: blood-borne virus; ED: emergency department; FBC: full blood count; HBV: hepatitis B virus; HCV: hepatitis C virus; RLTC: requiring 
linkage to care.
a Any differences between the BBV totals and the infection-specific totals are due to co-infections (eight in total).
b One new HBV diagnosis and two known-disengaged HCV-RNA cases died after their status was confirmed; therefore, they are not included in 
the RLTC total.
c Percentages of cases achieving each linkage outcome are the proportions of all RLTC cases. As these outcomes are not mutually exclusive 
(e.g. to be partially linked one must also be notified) they can sum to more than 100%.
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or whose age was unclassified, and estimated p values 
using a likelihood ratio test (LRT).
BBV seroprevalence and demographic factors associated 
with positive BBV serology
Crude seroprevalence was estimated separately for 
all cases, new diagnoses, cases RLTC and fully linked 
cases, as the proportion among the total tested for 
each. In addition to BBV cases and the three infection-
specific cases, estimates of HCV-Ab seroprevalence 
are presented to facilitate comparison with published 
studies, since HCV RNA is relatively rarely reported. 
As the distribution of demographic variables varied 
between those tested and those not tested for BBVs, 
we adjusted for non-participation using survey weights 
based on the inverse probability of a patient who had a 
FBC being in each combination of age, sex and ethnic-
ity, once those patients with unclassified age and sex 
were excluded. Survey weights were applied in esti-
mations of both seroprevalence and demographic fac-
tors associated with positive BBV serology, described 
below. The intention of the weighted analyses were 
to derive adjusted estimates applicable to the whole 
Table 2
Baseline characteristics and factors associated with testing for blood-borne viruses among patients having a full blood 
count, hospital emergency department testing programme, London, United Kingdom, 2015–2016 (n = 65,136)
Characteristics
ED attendees FBC patients Patients tested for at least 2 BBVs
n % n % n % aOR (95% CI)a
Sex
Female 30,585 47 12,447 50 2,905 47 Ref
Male 34,543 53 12,532 50 3,306 53 1.2 (1.1–1.3)
Age (years)
18–39 39,356 60 11,026 44 2,870 46 Ref
40–59 15,687 24 6,982 28 1,877 30 1.0 (0.94–1.1)
60–89 9,202 14 6,314 25 1,361 22 0.76 (0.70–0.82)
Unclassifiedb 891 1 659 3 103 2 NA
Ethnicity
White British ethnicity 15,979 25 7,036 28 1,709 28 Ref
White other (incl. Irish) 11,092 17 3,078 12 819 13 1.1 (0.98–1.2)
Asian British/Asian other 17,953 28 6,721 27 1,749 28 1.1 (0.99–1.2)
Black British/Black other 5,268 8 2,233 9 603 10 1.1 (1.01–1.3)
Mixed or other 6,858 11 2,407 10 618 10 1.0 (0.93–1.2)
Ethnicity not recorded 7,986 12 3,506 14 713 11 0.78 (0.71–0.87)
Residence
Fixed address NA NA 24,181 97 6,056 98 Ref
No fixed address NA NA 800 3 155 2 0.80 (0.65–0.98)
Time of arrival in the ED
Daytime (08:00–19:59) 44,263 68 15,930 64 4,134 67 Ref
Night-time (20:00–07:59) 20,873 32 9,051 36 2,077 33 0.86 (0.81–0.91)
Day of arrival in the ED
Weekday 47,790 73 18,507 74 4,566 74 NA
Weekend 17,346 27 6,474 26 1,645 26 NA
Quartile of waiting time in the ED
Q1 (0–8 min) 16,341 25 7,879 32 1,881 30 NA
Q2 (9–19 min) 16,796 26 6,834 27 1,725 28 NA
Q3 (20–37 min) 15,724 24 5,232 21 1,312 21 NA
Q4 (38–805 min) 16,274 25 5,036 20 1,293 21 NA
Totalc 65,136 100 24,981 100 6,211 100 NA
aOR: adjusted odds ratio; BBV: blood-borne virus; CI: confidence interval; ED: emergency department; FBC: full blood count; incl.: including; 
min: minutes; NA: not applicable; Q: quartile; Ref: reference category.
a The aOR and 95% CI of having a BBV test was estimated using logistic regression. Likelihood ratio test p values: p < 0.0001 for sex, age 
and time of arrival and p = 0.0267 for no fixed address. Day of the week and waiting time were not included in the model, as they were not 
significantly associated with testing uptake in single variable analysis (p = 0.237 and p = 0.087, respectively).
b Age group was coded as unclassified for patients with an invalid date of birth (n = 430) or whose age was recorded as > 89 years (n = 461 
aged 90–111 years). Median (interquartile range) ages of patients with a valid age recorded were 34 (26–49) years old for ED attendees, 42 
(29–60) years old for FBC patients and 41 (29–57) years old for BBV-tested patients.
c Eight ED attendees with missing sex and one with a missing valid waiting time account for the differences between the overall total and the 
sum of their categories.
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population of patients requiring a FBC and not just 
those tested for BBVs.
To identify demographic factors associated with posi-
tive BBV serology we applied the general modelling 
process described above for BBV testing uptake, with 
some small differences: only demographic variables 
were considered, positive serology was used as the 
dependent variable in the regression model and, as 
survey weights were applied to the model, p values 
had to be estimated from a Wald test rather than a 
LRT. A model was fitted for all BBVs, as well as three 
separate infection-specific models for HCV RNA, HBV 
and HIV. Sex, age and ethnicity were included as inde-
pendent variables in all four models and having no 
fixed address was included only for BBV, HBV and HCV 
RNA. We used the robust (Huber-White) standard error 
when estimating parameters and their variances in the 
weighted logistic model and compared these with esti-
mates obtained from an unweighted model to confirm 
that weighting did not introduce model instability or 
materially change our conclusions. To avoid potential 
inflation of estimates that might arise due to data spar-
sity [27], we grouped cases into fewer age categories 
than reported elsewhere for this programme [26]. For 
the same reason, we also considered collapsing the 
‘White British’ and ‘White other’ ethnic categories to 
reduce uncertainty in the estimates for ethnicity in HBV 
arising from small counts in the reference category, but 
decided against this on the grounds that maintaining 
the distinction between these groups was epidemio-
logically important and that our checks concluded no 
additional instability had been introduced by doing so.
Linkage to care outcomes 6 months after testing and 
numbers needed to screen
LTC was described according to the number and propor-
tion of cases RLTC that had achieved the three sequen-
tial linkage outcomes by 30 January 2017. We calculated 
the NNS to identify one new diagnosis or to fully link a 
case to care by taking the inverse of the point estimate 
and 95% CI of adjusted prevalence among new diagno-
ses and fully linked cases, respectively [28].
Ethical statement
The reason for the ethics committee’s decision that a 
formal ethics application was not required, as well as 
the attempts to contact all patients who tested posi-
tive to notify them of their results and invite them for 
clinical review with appropriate referral, have been 
described previously [26].
Results
Patient characteristics and factors associated 
with BBV testing uptake
After removing duplicates and exclusions (n = 31,427) 
there were 65,136 unique ED attendances by patients 
that were predominantly young (60% were aged 18–39 
years and 14% were aged 60–89 years), of Asian British/
Asian other (28%) or White British (25%) ethnicity and 
male (53%). The 24,981 (38%) who went on to have a 
FBC had no difference by sex and an older age distri-
bution (44% aged 18–39 years and 25% aged 60–89 
years). The median age (interquartile range (IQR)) of 
patients with a valid age recorded was 34 (IQR: 26–49) 
years old among ED attendees, 42 (IQR: 29–60) years 
old among those who had a FBC and 41 (IQR: 29–57) 
years old among those tested for BBVs; furthermore, 
6,211 FBC patients were tested for two (n = 280) or 
three (n = 5,931) BBVs, giving a BBV testing uptake of 
25% (Figure, Table 2).
In the multivariable analysis, aOR of BBV testing were 
slightly elevated among FBC patients that were male 
(aOR: 1.2; 95% CI: 1.1–1.3) or of Black British/Black 
other ethnicity (aOR: 1.1; 95% CI: 1.0–1.3), compared to 
those who were female or White British, respectively. 
Patients ≥ 60 years old (aOR: 0.78; 95% CI: 0.71–0.87), 
with no fixed address (aOR: 0.80; 95% CI: 0.65–0.98), 
whose ethnicity was not recorded (aOR: 0.78; 95% CI: 
0.71–0.87) or who arrived in the ED at night (aOR: 0.86; 
95% CI: 0.81–0.91) had lower aOR of BBV testing than 
those who were aged 18–39 years, White British, had a 
fixed address or arrived in the day, respectively (Table 
2).
Seroprevalence and factors associated with 
positive BBV serology
There were 217 BBV cases identified among the 6,211 
patients tested (3.5%), resulting in an estimated over-
all adjusted BBV seroprevalence of 4.2% (95% CI: 
3.6–4.9) in FBC patients. Three cases were co-infected 
with HBV and HIV, and five with HCV and HIV; no HBV-
HCV co-infections were detected. The adjusted sero-
prevalence was 1.6% (95% CI: 1.3–2.1) in the 86 cases 
RLTC and 0.7% (95% CI: 0.4–1.0) in the 31 new BBV 
diagnoses.
Elevated aOR of positive BBV serology were estimated 
in FBC patients that were male (aOR: 2.7; 95% CI: 1.9–
3.9), aged 40–59 years (aOR: 1.9; 95% CI: 1.4–2.7), of 
Black British/Black other ethnicity (aOR: 1.8; 95% CI: 
1.2–2.8) or who had no fixed address (aOR: 2.9; 95% 
CI: 1.5–5.5), compared to patients in the reference cat-
egories of female, aged 18–49 years, White British or of 
fixed address, respectively (Table 3).
Diagnostic status and linkage to care outcomes 
among BBV cases
Over half of the 217 BBV cases were classified as 
known-engaged (129 cases; 59%), with much smaller 
proportions of known-disengaged (32 cases; 15%) and 
new diagnoses (31 cases; 14%). The remaining 25 cases 
(12%) were either uncontactable or known-unknown.
Among the 86 cases RLTC (40% of the 217 BBV cases), 
58 (67%) were notified of their diagnosis, 47 (55%) were 
partially linked to care and 35 (41%) were fully linked 
to care. BBV cases with no fixed address were few in 
number (19/217 cases), but were disproportionately 
hard to follow-up, with over half (11 cases) remaining 
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uncontactable and only one notified of their test result 
(Figure).
Numbers needed to screen
NNS to detect a new BBV diagnosis was 154 (95% CI: 
103–233) and to fully link a BBV case to care was 135 
(95% CI: 93–200).
Summary of infection-specific results
Seroprevalence and factors associated with positive 
serology
Infection-specific adjusted seroprevalence was esti-
mated at 2.6% (95% CI: 2.2–3.2; n = 147) for HCV-Ab, 
1.8% (95% CI: 1.4–2.2; n = 100) for HCV RNA, 1.5% 
(95% CI: 1.2–2.0; n = 71) for HIV and 1.1% (95% CI: 
0.8–1.5; n = 54) for HBV. There was no significant dif-
ference between the adjusted estimates of seropreva-
lence among new diagnoses for HCV RNA (0.3%; 95% 
CI: 0.2–0.5; n = 13), HBV (0.1%; 95% CI: 0.1–0.3; n = 8) 
and HIV (0.3%; 95% CI: 0.1–0.5; n = 10). Adjusted prev-
alence among cases RLTC was highest for HCV RNA 
(0.8%; 95% CI: 0.6–1.1; n = 44), followed by HBV (0.5%; 
95% CI: 0.3–0.8; n = 27) then HIV (0.4%; 95% CI: 0.2–
0.6; n = 16).
Being male, 40–59 years old or having no fixed address 
were all associated with increased adjusted odds of 
positive HCV-RNA serology. For HIV, males were more 
likely and older patients (60–89 years) were less likely 
to be positive. There was no association between 
positive HBV serology and age, sex or having a fixed 
address, in the multivariable analysis. Associations 
with ethnicity varied by infection; the Asian British/
Asian other group was less likely to be positive for 
both HCV RNA and HIV, whereas the Black British/
Black other group was associated with reduced odds 
of HCV RNA, but increased odds of positive HIV serol-
ogy. There was considerable uncertainty in the esti-
mates for HBV due to small counts in the White British 
Table 3
Seroprevalence of blood-borne viruses and demographic factors associated with positive BBV serology among patients 
having a full blood count, hospital emergency department testing programme, London, United Kingdom, 2015–2016 
(n = 217)
Characteristic Number tested
All cases New diagnoses RLTC
n
Prevalence 
 
% (95% CI)
aOR (95% CI)a n
Prevalence 
 
% (95% CI)
n
Prevalence 
 
% (95% CI)
Sex
Female 2,905 51 1.8 (1.3–4.0) Ref 8 0.3 (0.1–0.6) 21 0.7 (0.5–1.1)
Male 3,306 166 5.0 (4.3–5.8) 2.7 (1.9–3.9) 23 0.7 (0.5–1.0) 65 2.0 (1.5–2.5)
Age (years)
18–39 2,870 78 2.7 (2.2–3.4) Ref 11 0.4 (0.2–0.7) 29 1.0 (0.7–1.5)
40–59 1,877 110 5.9 (4.9–7.0) 1.9 (1.4–2.7) 16 0.9 (0.5–1.4) 45 2.4 (1.8–3.2)
60–89 1,361 26 1.9 (1.3–2.8) 0.88 (0.53–1.5) 4 0.3 (0.1–0.8) 9 0.7 (0.3–1.3)
Unclassified 103 3 2.9 (0.9–8.6) NA 0 0 3 2.9 (0.9–8.6)
Ethnicity
White British 1,709 64 3.7 (2.9–4.8) Ref 6 0.4 (0.2–0.8) 23 1.3 (0.9–2.0)
White other (incl. Irish) 819 43 5.3 (3.9–7.0) 1.5 (1.0–2.4) 10 1.2 (0.7–2.3) 24 2.9 (2.0–4.3)
Asian British/Asian 1,749 23 1.3 (0.9–2.0) 0.36 (0.22–0.60) 4 0.2 (0.1–0.6) 9 0.5 (0.3–1.0)
Black British/Black 603 42 7.0 (5.2–9.3) 1.8 (1.2–2.8) 5 0.8 (0.4–2.0) 10 1.7 (0.9–3.1)
Mixed or other 618 27 4.4 (3.0–6.3) 1.1 (0.69–1.9) 4 0.7 (0.2–1.7) 11 1.8 (1.0–3.2)
Ethnicity not recorded 713 18 2.5 (1.6–4.0) 0.55 (0.29–1.0) 2 0.3 (0.1–1.1) 9 1.3 (0.7–2.4)
Residence
Fixed address 6,056 198 3.3 (2.9–3.8) Ref 31 0.5 (0.4–0.7) 74 1.2 (1.0–1.5)
No fixed address 155 19 12.3 (8.0–18.4) 2.9 (1.5–5.5) 0 0 12 7.7 (4.5–13.1)
Total (crude)b 6,211 217 3.5 (3.1–4.0) NA 31 0.5 (0.4–0.7) 86 1.4 (1.1–1.7)
Total (adjusted)c 6,108 214 4.2 (3.6–4.9) NA 31 0.7 (0.4–1.0) 83 1.6 (1.3–2.1)
aOR: adjusted odds ratio; BBV: blood-borne virus; CI: confidence interval; NA: not applicable; Ref: reference; RLTC: requiring linkage to care.
a aOR and 95% CI for the association between demographic factors and positive serology for at least one blood-borne virus (HIV, HBV and/or 
HCV RNA). Estimates were weighted to reflect the age, sex and ethnicity of the FBC population, after excluding those with unclassified age 
and sex (n = 24,321). Wald test p values: p < 0.0001 for sex and ethnicity, p = 0.0001 for age and p = 0.0017 for no fixed address.
b The 217 BBV cases were unique patients including eight co-infections.
c Adjusted prevalence estimates were weighted to reflect the age, sex and ethnicity of the FBC population, after excluding those with 
unclassified age and sex (n = 24,321).
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reference category, but both the crude seroprevalence 
estimates and the aOR from the multivariable analy-
sis pointed to elevated odds of positive HBV serology 
among the White other, Black British/Black other, Asian 
British/Asian other and Mixed or other ethnic groups 
(Supplementary Tables S1, S2 and S3).
Diagnostic status and linkage to care
For each infection, the highest proportion of cases 
were classified as known-engaged, ranging from 
48% for HBV to 77% for HIV. For the three infections, 
13–15% of cases were new diagnoses. The proportion 
of cases RLTC was lowest for HIV (23%; 16/71 cases), 
followed by HCV RNA (44%; 44/100 cases) and HBV 
(50%; 27/54 cases). HIV cases remained unlinked less 
often than the others (4/16 RLTC compared with 10/27 
HBV and 14/44 HCV) and had the highest proportion 
of fully linked cases (69%), though the total number of 
fully linked cases for each infection were very similar 
(Figure).
Numbers needed to screen
NNS to detect a new diagnosis were 400 (95% CI: 204–
769) for HIV, 833 (95% CI: 370–1,667) for HBV and 357 
(95% CI: 185–667) for HCV RNA, and to fully link a case 
to care were 385 (95% CI: 208–714) for HIV, 588 (95% 
CI: 294–1,111) for HBV and 313 (95% CI: 167–588) for 
HCV RNA.
Discussion
This programme resulted in the identification of 217 
BBV cases from 6,211 patients tested for at least two 
of the three selected BBVs, giving an adjusted estimate 
of overall BBV seroprevalence among patients who had 
a FBC of 4.2% (95% CI: 3.6–4.9). Elevated aOR of posi-
tive BBV serology were estimated in FBC patients that 
were male (2.7; 95% CI: 1.9–3.9), 40–59 years old (1.9; 
95% CI: 1.4–2.7), of Black British/Black other ethnic-
ity (1.8; 95% CI: 1.2–2.8) or who had no fixed address 
(2.9; 95% CI: 1.5–5.5). We estimated that 154 (95% CI: 
103–233) FBC patients needed to be screened to detect 
one new BBV diagnosis and 135 (95% CI: 93–200) 
needed to be screened to detect a BBV case that was 
fully linked to care.
The implementation of this programme as part of 
normal workflows in an ED introduced a number of 
limitations. Only routinely collected demographic infor-
mation was recorded, which meant that we were unable 
to account for known risk factors, such as those of peo-
ple who inject drugs (PWID) [3,10,11] or men who have 
sex with men (MSM) [3,9]. Originating from a country 
where BBVs are more prevalent [3,29-32] has been 
postulated as a predictor of infection rates similar to 
those in the country of origin [11]. Self-reported ethnic-
ity, as collected in this programme, may be a less reli-
able determinant of disease risk than country of birth 
and time spent in the UK [33,34]—neither of which were 
recorded in the ED. Further, small numbers of cases, 
particularly for HBV, may have led to missed asso-
ciations between demographic factors and positive 
disease serology due to low statistical power. In addi-
tion, patients could only be recruited for testing via 
convenience sampling; such non-probability sampling 
is prone to selection bias and the differential BBV test-
ing uptake that we identified among certain groups, as 
reported elsewhere [17,19], may be evidence of this. 
Unlike in other studies [19], reasons for not testing were 
not recorded; relevant factors might include patients’ 
refusal, a previous diagnosis, inconsistent offering of 
testing or targeting of particular groups, all of which 
could bias our estimates in different ways. However, 
the use of weighting to adjust for non-participation in 
testing aimed to address this and is an improvement 
over previous ED-based programmes that have only 
reported crude prevalence [17,18,23-25].
The demographic factors we identified as associated 
with positive BBV serology were broadly in line with 
those reported previously for London and England 
[3,4,8-11,28,34]. One exception is our finding of Asian 
British/Asian other ethnicity (which was dominated 
by Bangladeshis, followed by ‘other Asian’, Indians, 
Pakistanis and a small number of Chinese) being 
strongly protective against positive HCV serology; this 
runs counter to modelled estimates that show HCV prev-
alence among those who are not PWID in London to be 
much higher in people of south Asian ethnicity than all 
other ethnic groups [11]. Unmeasured MSM status may 
partly explain the elevated odds of HIV we detected 
among males, since HIV prevalence among MSM in 
London (13.5%) is estimated to be around four times 
higher than in the rest of England and Wales (3.9%) 
[14]. There was less clear agreement between our sero-
prevalence estimates and published estimates of prev-
alence in those aged 15–59 years in London for HCV-Ab 
(1.2%) [11] and diagnosed HIV (0.6%) [12]. We obtained 
much higher estimates for our population who had a 
FBC and were aged 18–59 years for HIV (1.9%; 1.5–2.5) 
and HCV-Ab (2.8%; 2.3–3.4). Our elevated prevalence 
estimates may by partly due to a genuinely higher 
underlying HCV and HIV prevalence in the area served 
by the hospital, as compared to the rest of London; 
however, it is also highly unlikely that ED attendees, 
and the subset of them that require a FBC, represent 
the general population of either the hospital’s catch-
ment area or the rest of London, in terms of risk fac-
tors for BBVs. With the exception of HCV-Ab prevalence 
estimated from an ED in Dublin (5.1%; 95% CI: 4.6–5.5) 
that was more than twice as high as we observed [23], 
there was, strong agreement between our crude esti-
mates of infection-specific seroprevalence and those 
reported from previous urban ED testing campaigns in 
London (all BBVs) [17,18,35], Dublin (HIV and HBV) [23], 
Germany (HCV-Ab) [25], Switzerland (HCV-Ab) [24] and 
the Netherlands (HIV) [36].
Numerous lessons for ED-based testing programmes 
have emerged from this work. Our low testing uptake 
might be improved by investigating and adopting the 
methods used in hospitals that previously reported 
higher rates [17,19,23]; one promising approach is a 
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pre-selected test-ordering IT system used in a recent 
ED-based programme in London, which reported 56% 
testing uptake [35]. A major limitation of our pro-
gramme was that over half of the BBV cases we identi-
fied were already engaged in care; detection of these is 
useful for understanding seroprevalence, but is waste-
ful if the objective of a programme is to find cases 
RLTC, which is where the main public health return on 
investment (ROI) lies. Approaches to exclude known-
engaged patients could include asking about recent 
testing [37] or the use of an automatic hospital record 
check, although the feasibility of either approach in a 
busy ED would need to be assessed and some patients 
may not always choose to disclose their status and be 
tested anyway. Targeted testing of groups known to be 
at the highest risk of BBV infection, including those 
identified in this study, may also improve the ROI of 
future programmes, though it would be advisable to 
evaluate the sensitivity of targeted vs universal screen-
ing [22] and to first decide what is an acceptable level 
of missed diagnoses. Cases with no fixed address were 
particularly hard to contact and therefore link to care. 
LTC rates might therefore be improved through the use 
of community settings, such as homeless outreach 
services or needle exchange centres, to contact and 
inform those who are homeless or currently injecting 
drugs of their diagnoses, carry out clinical assess-
ments and discuss treatment options.
Conclusion
In conclusion, the low NNS estimated by this pro-
gramme suggest routine BBV screening in the ED may 
be worthwhile, though a formal cost-effectiveness 
appraisal, which was beyond the scope of this work, 
is advisable. We identified high BBV seroprevalence, 
in line with previously reported estimates from simi-
lar programmes in Western Europe. Our adjusted esti-
mates of seroprevalence and demographic factors 
associated with positive BBV serology are likely to be 
generalisable to patients having a FBC in EDs in London 
or other large UK cities, and may be relevant to EDs in 
Western European cities with BBV epidemiology simi-
lar to London’s. Those considering similar programmes 
should use our findings to inform their assessments of 
the anticipated public health benefits of the interven-
tion and in the planning of its delivery.
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